WO2024068996 - ANTI-SARS-COV-2 ANTIBODIES AND USE THEREOF IN THE TREATMENT OF SARS-COV-2 INFECTION
National phase entry is expected:
Publication Number
WO/2024/068996
Publication Date
04.04.2024
International Application No.
PCT/EP2023/077174
International Filing Date
29.09.2023
Title **
[English]
ANTI-SARS-COV-2 ANTIBODIES AND USE THEREOF IN THE TREATMENT OF SARS-COV-2 INFECTION
[French]
ANTICORPS ANTI-SARS-COV-2 ET UTILISATION ASSOCIÉE DANS LE TRAITEMENT D'UNE INFECTION PAR SARS-COV-2
Applicants **
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (C.H.U.V.)
ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL)
Inventors
PANTALEO, Giuseppe
FENWICK, Craig W.
TRONO, Didier P.
TURELLI, Priscilla
Priority Data
22199188.8
30.09.2022
EP
63/506,285
05.06.2023
US
63/506,352
05.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4600 | |
| EPO | Filing, Examination, Granting | 49066 | |
| Japan | Filing, Examination, Granting | 3695 | |
| South Korea | Filing, Examination, Granting | 5280 | |
| USA | Filing, Examination, Granting | 23040 |
Total:
85,681
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure provides antibodies, or antigen-binding fragments thereof, and use thereof in prophylaxis, treatment and/or attenuation of a SARS-CoV-2 virus infection.[French]
La divulgation concerne des anticorps ou des fragments de liaison à l'antigène de ceux-ci, ainsi qu'une utilisation associée dans la prophylaxie, le traitement et/ou l'atténuation d'une infection par le virus SARS-CoV-2.